Summary
Signal counts
Assets tracked: 3
Watchlist assets: 3
Registry stop assets: 3
Sponsor overview
H. Lee Moffitt Cancer Center and Research Institute
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00604461 | https://clinicaltrials.gov/study/NCT00776295 | https://clinicaltrials.gov/study/NCT00495625
Assets
Linked programs
- Carboplatin, Bevacizumab and Pemetrexed: Registry Stop Signal (4/5)
- Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes: Registry Stop Signal (4/5)
- Sunitinib Malate: Registry Stop Signal (4/5)